Physician profile
Sumedha Dalvi
NPI 1255400321
$23,771.47
in general payments reported to CMS, 2019-2025
61 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,738 · 2020: $2,344 · 2021: $3,772 · 2022: $3,427 · 2023: $2,654 · 2024: $3,486 · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,490.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,232.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $2,401.85 | 2019-2025 | Otezla, Otezla, Repatha |
| Novo Nordisk INC | $1,983.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,559.43 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $1,545.06 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $912.03 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $820.10 | 2019-2025 | |
| Abbvie INC. | $798.67 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $696.14 | 2019-2025 | |
| Eisai INC. | $610.35 | 2020-2025 | |
| Abbott Laboratories | $601.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Penta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.49 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $578.44 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Medtronic, INC. | $490.81 | 2022-2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $479.12 | 2021-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumedha Dalvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.